Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Yumanity Therapeutics Inc.
Headquarters: Boston, MA, United States of America
Website: N/A
Year Founded: 2014
Status: Reverse-merged
BioCentury | Jul 28, 2023
Deals
Biotech reverse mergers growing amid improving market conditions
Are 2023’s reverse mergers another sign of an improving biotech environment?
BioCentury | Jun 29, 2023
Deals
Janssen says half pipeline value will come from outside
What the last two years of BD reveal about the kind of innovation J&J is seeking, and where it’s finding opportunities
BioCentury | Jun 6, 2022
Deals
Sale of programs to J&J leaves Yumanity as shell for Kineta reverse merger
Combined company to advance Seattle biotech’s cancer programs as Yumanity’s eight-year history in neurodegeneration comes to a close
BioCentury | Feb 18, 2022
Product Development
Feb. 17 Quick Takes: Agios wins FDA approval in rare anemia
Plus updates from Arvinas, BMS, Innovent, Ironwood, Deerfield, Yumanity
BioCentury | Aug 17, 2021
Management Tracks
Spark alum Couto joins Atsena as CSO
Plus: Novavax, ImmunityBio, Freeline, ReCode, Yumanity
BioCentury | Jun 14, 2021
Management Tracks
J&J’s Burton named Moderna CMO; plus Editas, Athira, Yumanity and more
Paul Burton will become CMO at Moderna Inc. (NASDAQ:MRNA) on July 6, succeeding Tal Zaks. Burton is a 16-year veteran of Johnson & Johnson (NYSE:JNJ), most recently serving as chief global medical
BioCentury | Apr 15, 2021
Management Tracks
New CSO at Everest; plus Wugen, Evelo, Inflammatix, ImCheck and more
Cross-border licensing company Everest Medicines Ltd. (HKEX:1952) hired Jennifer Yang as CSO. Yang was previously VP and head of China for the lung cancer initiative at Johnson & Johnson
BioCentury | Jun 25, 2020
Deals
June 24 Quick Takes: CSL pays $450M for uniQure’s hemophilia gene therapy; plus Merck-Yumanity, Editas, Compass-Olivia, Century-Empirica, Tetraphase-La Jolla
BioCentury | Nov 20, 2019
Company News
Management tracks: Vifor, Relay, I-Mab, Yumanity, Savara and more
BioCentury | Sep 9, 2019
Company News
Management tracks: Coles to lead Cerevel; plus Genfit, Jubilant, Paratek, Mogrify, Dementia Discovery Fund and Ayala
Items per page:
1 - 10 of 17